Kintor Pharma 
Welcome,         Profile    Billing    Logout  
 2 Products   14 Diseases  2 Products   8 Trials   95 News 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ascrinvacumab (GT90001) / Kintor Pharma
NCT05178043: GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma

Active, not recruiting
2
5
US
Nivolumab, Opdivo, ONO-4538, BMS-936558, MDX1106, GT90001, PF-03446962
Suzhou Kintor Pharmaceutical Inc,
Hepatocellular Carcinoma, HCC
04/25
12/25
NCT03893695: Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)

Completed
1/2
20
RoW
GT90001 and Nivolumab, GT90001 and Opdivo
Suzhou Kintor Pharmaceutical Inc,
Metastatic Hepatocellular Carcinoma, HCC, Combinations of Drugs; Dependence
05/22
09/22
NCT04984668: A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors

Recruiting
1/2
216
RoW
GT90001+KN046, GT90001/KN046
Suzhou Kintor Pharmaceutical Inc,, Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Solid Tumor
04/25
12/25
pruxelutamide (GT0918) / Kintor Pharma
NCT04869228: A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients

Terminated
3
380
RoW
GT0918 tablets or placebo
Suzhou Kintor Pharmaceutical Inc,
COVID-19
09/22
08/23
NCT05009732: A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects

Terminated
3
139
US, RoW
GT0918, Proxalutamide, Standard of care, SoC, Matching placebo, Placebo
Suzhou Kintor Pharmaceutical Inc,
Covid19
02/23
07/23
NCT05076851: Neoadjuvant Therapy With Proxalutamide Combined With Androgen Deprivation Therapy（ADT）for High Risk Prostate Cancer

Recruiting
2
2
RoW
placebo, Proxalutamide
Hongqian Guo
Neoadjuvant Therapy \High Risk Prostate Cancer
12/21
10/22
NCT03899467: The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Completed
2
61
US
GT0918, proxalutamide, androgen receptor antagonist
Suzhou Kintor Pharmaceutical Inc,
Metastatic Castrate Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
03/22
09/22
GT0918-CN-2002, CTR20191063: Phase Ic study of the safety, pharmacodynamics and efficacy of proxalutamide combined with endocrine drugs in patients with hormone receptor-positive and androgen receptor-positive metastatic breast cancer

Completed
1c
78
China
pruxelutamide (GT0918) - Kintor Pharma, letrozole - Generic mfg., exemestane - Generic mfg., fulvestrant - Generic mfg.
Suzhou Kaituo Pharmaceutical Co., Ltd./China Pharmaceutical University
Breast cancer;Oncology
 
 
ChiCTR2200061250: A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Severe or Critical COVID-19 Subjects

Recruiting
N/A
 
Zhongshan Hospital Fudan University; Zhongshan Hospital Fudan University, Suzhou Kintor Pharmaceuticals Inc.
COVID-19
 
 
pyrilutamide (KX0826) / Kintor Pharma
NCT06126965: Phase III Study of KX-826 With Adult Male Patients With AGA

Active, not recruiting
3
740
RoW
KX-826-（5%） BID, KX-826-5 mg(5%)60mL BID, Placebo
Suzhou Kintor Pharmaceutical Inc,, Suzhou Koshine Biomedica, Inc.
Androgenetic Alopecia
05/24
05/24
NCT06622824: To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia

Not yet recruiting
2/3
756
RoW
KX-826 0.5% BID, KX-826 1.0% BID, Vehicle (Placebo) applied BID
Suzhou Kintor Pharmaceutical Inc,, Suzhou Koshine Biomedica, Inc.
Androgenetic Alopecia (AGA)
10/27
06/28
NCT05940506: Phase II Study Evaluating the Efficacy and Safety of KX-826

Completed
2
120
RoW
KX-826-2.5 mg (0.25%)/60 mL BID, KX-826-2.5 mg (0.25%)/60 mL, KX-826-5 mg (5%)/60 mL QD, KX-826-5 mg (5%)/60 mL BID, Placebo
Suzhou Kintor Pharmaceutical Inc,
Androgenetic Alopecia (AGA)
07/21
08/21
NCT06409650: To Evaluate Safety and Efficacy of KX-826 in Chinese Female Subjects With Androgenetic Alopecia

Completed
2
160
RoW
KX-826 dosed at 2.5mg, KX-826 dosed at 5 mg, Matching placebo to KX-826
Suzhou Koshine Biomedica, Inc.
Alopecia
11/22
12/23
NCT05218642: To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia

Completed
2
123
US
KX- 826 dosed at 2.5mg, KX-826 dosed at 5mg, Matching placebo to KX-826
Suzhou Kintor Pharmaceutical Inc,
Alopecia, Male Pattern Hair Loss
02/23
02/23
GT20029 / Kintor Pharma
NCT06692465: To Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males

Completed
2
180
RoW
GT20029 Tincture, GT20029 matching placebo
Suzhou Kintor Pharmaceutical Inc,, Suzhou Koshine Biomedica, Inc.
Alopecia, Male Pattern Hair Loss
12/23
06/24
NCT06468579: To Evaluate the Safety, Tolerability and PK of GT20029 Gel and Solution in Healthy Subjects

Completed
1
92
RoW
GT20029, GT20029 matching placebo
Suzhou Kintor Pharmaceutical Inc,
Acne, Alopecia
08/22
04/23
NCT05428449: Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029

Completed
1
123
US
GT20029 Gel, GT20029 Gel Placebo
Suzhou Kintor Pharmaceutical Inc,
Androgenetic Alopecia, Acne Vulgaris
10/22
04/23
GT90008 / Suzhou Zelgen
No trials found
detorsertib (GT0486) / Kintor Pharma
No trials found
Undisclosed ALK-1/VEGF bispecific antibody / Kintor Pharma
No trials found
GT19715 / Kintor Pharma
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ascrinvacumab (GT90001) / Kintor Pharma
NCT05178043: GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma

Active, not recruiting
2
5
US
Nivolumab, Opdivo, ONO-4538, BMS-936558, MDX1106, GT90001, PF-03446962
Suzhou Kintor Pharmaceutical Inc,
Hepatocellular Carcinoma, HCC
04/25
12/25
NCT03893695: Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)

Completed
1/2
20
RoW
GT90001 and Nivolumab, GT90001 and Opdivo
Suzhou Kintor Pharmaceutical Inc,
Metastatic Hepatocellular Carcinoma, HCC, Combinations of Drugs; Dependence
05/22
09/22
NCT04984668: A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors

Recruiting
1/2
216
RoW
GT90001+KN046, GT90001/KN046
Suzhou Kintor Pharmaceutical Inc,, Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Solid Tumor
04/25
12/25
pruxelutamide (GT0918) / Kintor Pharma
NCT04869228: A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients

Terminated
3
380
RoW
GT0918 tablets or placebo
Suzhou Kintor Pharmaceutical Inc,
COVID-19
09/22
08/23
NCT05009732: A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects

Terminated
3
139
US, RoW
GT0918, Proxalutamide, Standard of care, SoC, Matching placebo, Placebo
Suzhou Kintor Pharmaceutical Inc,
Covid19
02/23
07/23
NCT05076851: Neoadjuvant Therapy With Proxalutamide Combined With Androgen Deprivation Therapy（ADT）for High Risk Prostate Cancer

Recruiting
2
2
RoW
placebo, Proxalutamide
Hongqian Guo
Neoadjuvant Therapy \High Risk Prostate Cancer
12/21
10/22
NCT03899467: The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Completed
2
61
US
GT0918, proxalutamide, androgen receptor antagonist
Suzhou Kintor Pharmaceutical Inc,
Metastatic Castrate Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
03/22
09/22
GT0918-CN-2002, CTR20191063: Phase Ic study of the safety, pharmacodynamics and efficacy of proxalutamide combined with endocrine drugs in patients with hormone receptor-positive and androgen receptor-positive metastatic breast cancer

Completed
1c
78
China
pruxelutamide (GT0918) - Kintor Pharma, letrozole - Generic mfg., exemestane - Generic mfg., fulvestrant - Generic mfg.
Suzhou Kaituo Pharmaceutical Co., Ltd./China Pharmaceutical University
Breast cancer;Oncology
 
 
ChiCTR2200061250: A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Severe or Critical COVID-19 Subjects

Recruiting
N/A
 
Zhongshan Hospital Fudan University; Zhongshan Hospital Fudan University, Suzhou Kintor Pharmaceuticals Inc.
COVID-19
 
 
pyrilutamide (KX0826) / Kintor Pharma
NCT06126965: Phase III Study of KX-826 With Adult Male Patients With AGA

Active, not recruiting
3
740
RoW
KX-826-（5%） BID, KX-826-5 mg(5%)60mL BID, Placebo
Suzhou Kintor Pharmaceutical Inc,, Suzhou Koshine Biomedica, Inc.
Androgenetic Alopecia
05/24
05/24
NCT06622824: To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia

Not yet recruiting
2/3
756
RoW
KX-826 0.5% BID, KX-826 1.0% BID, Vehicle (Placebo) applied BID
Suzhou Kintor Pharmaceutical Inc,, Suzhou Koshine Biomedica, Inc.
Androgenetic Alopecia (AGA)
10/27
06/28
NCT05940506: Phase II Study Evaluating the Efficacy and Safety of KX-826

Completed
2
120
RoW
KX-826-2.5 mg (0.25%)/60 mL BID, KX-826-2.5 mg (0.25%)/60 mL, KX-826-5 mg (5%)/60 mL QD, KX-826-5 mg (5%)/60 mL BID, Placebo
Suzhou Kintor Pharmaceutical Inc,
Androgenetic Alopecia (AGA)
07/21
08/21
NCT06409650: To Evaluate Safety and Efficacy of KX-826 in Chinese Female Subjects With Androgenetic Alopecia

Completed
2
160
RoW
KX-826 dosed at 2.5mg, KX-826 dosed at 5 mg, Matching placebo to KX-826
Suzhou Koshine Biomedica, Inc.
Alopecia
11/22
12/23
NCT05218642: To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia

Completed
2
123
US
KX- 826 dosed at 2.5mg, KX-826 dosed at 5mg, Matching placebo to KX-826
Suzhou Kintor Pharmaceutical Inc,
Alopecia, Male Pattern Hair Loss
02/23
02/23
GT20029 / Kintor Pharma
NCT06692465: To Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males

Completed
2
180
RoW
GT20029 Tincture, GT20029 matching placebo
Suzhou Kintor Pharmaceutical Inc,, Suzhou Koshine Biomedica, Inc.
Alopecia, Male Pattern Hair Loss
12/23
06/24
NCT06468579: To Evaluate the Safety, Tolerability and PK of GT20029 Gel and Solution in Healthy Subjects

Completed
1
92
RoW
GT20029, GT20029 matching placebo
Suzhou Kintor Pharmaceutical Inc,
Acne, Alopecia
08/22
04/23
NCT05428449: Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029

Completed
1
123
US
GT20029 Gel, GT20029 Gel Placebo
Suzhou Kintor Pharmaceutical Inc,
Androgenetic Alopecia, Acne Vulgaris
10/22
04/23
GT90008 / Suzhou Zelgen
No trials found
detorsertib (GT0486) / Kintor Pharma
No trials found
Undisclosed ALK-1/VEGF bispecific antibody / Kintor Pharma
No trials found
GT19715 / Kintor Pharma
No trials found

Download Options